Complement Therapeutics, a Munich, Germany-based preclinical biotech startup, secured €72M ($78.9M) in Series A funding.
The firm is developing novel therapeutics for complement-mediated diseases. The majority of the funds will be used to complete the Phase 1b clinical proof of concept for its lead candidate CTx001, which is aimed at treating Geographic Atrophy (GA).
- Complement spun out from the University of Manchester.
- It raised €5M ($5.4M) in seed funding in February 2022 from Forbion and BGV.
- Gimv and Forbion co-led the funding round, with participation from BioGeneration Ventures (BGV), Panakès Partners, Cambridge Innovation Capital (CIC), Hadean Ventures, and Seroba Life Sciences.
- Funds from the current round will also be used to scale its laboratory-based activities and further develop the Complement Precision Medicine platform.
